{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:36:05Z","timestamp":1793262965564,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,5]],"date-time":"2027-09-05T00:00:00Z","timestamp":1820102400000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jiac.2026.103065","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:48:44Z","timestamp":1788565724000},"page":"103065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary nocardiosis following pembrolizumab use: case report and literature review of nocardiosis associated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"32","author":[{"given":"Takashi","family":"Koyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei Furui","family":"Ebisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Mizobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goh","family":"Ohji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsugumi","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103065_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jiac.2026.103065_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103065_bib3","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2026.103065_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jiac.2026.103065_bib5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2217\/imt-2022-0152","article-title":"A case report of pulmonary nocardiosis during pembrolizumab: the emerging challenge of the infections on immunotherapy","volume":"14","author":"Lasagna","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jiac.2026.103065_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12879-022-07288-4","article-title":"Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report","volume":"22","author":"Petitgas","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib7","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1159\/000541694","article-title":"Pulmonary nocardiosis in a non-small cell lung cancer patient being treated for pembrolizumab-associated pneumonitis","volume":"17","author":"Quartermain","year":"2024","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jiac.2026.103065_bib8","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1093\/cid\/ciae643","article-title":"State-of-the-Art review: modern approach to Nocardiosis\u2014Diagnosis, management, and uncertainties","volume":"80","author":"Yetmar","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2018.06.014","article-title":"Nocardiosis in a patient with anti-PD-1\u2013associated colitis treated with infliximab","volume":"101","author":"Glutsch","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiac.2026.103065_bib10","first-page":"1470","article-title":"Disseminated nocardiosis occurring in the course of treatment of immunerelated Adverse Events associated with malignant pleural mesothelioma","volume":"66","author":"Okaniwa","year":"2024","journal-title":"Rinsho derma(Tokyo)"},{"key":"10.1016\/j.jiac.2026.103065_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2026.103065_bib13","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1002\/cam4.3532","article-title":"Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy","volume":"9","author":"Kanjanapan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jiac.2026.103065_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","article-title":"Infectious complications in patients treated with immune checkpoint inhibitors","volume":"141","author":"Karam","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiac.2026.103065_bib15","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jiac.2026.103065_bib16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/ijms23031619","article-title":"PD-L1 expression in monocytes correlates with bacterial burden and treatment outcomes in active pulmonary tuberculosis","volume":"23","author":"Pan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiac.2026.103065_bib17","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.21037\/jtd-23-1395","article-title":"A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does goldilocks have the answer?","volume":"16","author":"Vaddi","year":"2024","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jiac.2026.103065_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.riam.2023.05.001","article-title":"Necrotizing pneumonia due to Aspergillus and Salmonella after immune checkpoint inhibitor treatment: an unusual case and review of the literature","volume":"40","author":"I\u015f\u0131k","year":"2023","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.jiac.2026.103065_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107697","article-title":"Increased expression of the PD-1\/PD-L1 regulatory axis in tissue leukocytes from experimental actinomycetoma by Nocardia brasiliensis in BALB\/c mice","volume":"205","author":"V\u00e1zquez-Marmolejo","year":"2025","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jiac.2026.103065_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1129730","article-title":"Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the FAERS database","volume":"14","author":"Xia","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2026.103065_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/fmb.09.116","article-title":"Current understanding of Pneumocystis immunology","volume":"5","author":"Kelly","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jiac.2026.103065_bib23","doi-asserted-by":"crossref","unstructured":"Kantheti U, Forward TS, Lucas ED, Schafer JB, Tamburini PJ, Burchill MA et al. PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration. Sci Adv; 11: eadt3044.","DOI":"10.1126\/sciadv.adt3044"},{"key":"10.1016\/j.jiac.2026.103065_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiac.2026.103065_bib25","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3389\/fimmu.2018.02922","article-title":"Blockade of LAG-3 immune checkpoint combined with therapeutic vaccination restore the function of tissue-resident anti-viral CD8+ T cells and protect against recurrent ocular Herpes Simplex infection and disease","volume":"9","author":"Roy","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2026.103065_bib26","doi-asserted-by":"crossref","unstructured":"Traxler RM, Bell ME, Lasker B, Headd B, Shieh W-J, McQuiston JR. Updated review on nocardia species: 2006\u20132021. Clin Microbiol Rev; 35: e00027-21.","DOI":"10.1128\/cmr.00027-21"},{"key":"10.1016\/j.jiac.2026.103065_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2020.12.019","article-title":"How do I manage nocardiosis?","volume":"27","author":"Margalit","year":"2021","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.jiac.2026.103065_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12883-024-03826-6","article-title":"Brain abscesses: the first report of disseminated Nocardia beijingensis infection in an immunocompetent individual in China","volume":"24","author":"Jin","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jiac.2026.103065_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1556\/1886.2024.00110","article-title":"Nocardia wallacei: a rare cause of actinomycetoma in an immunocompetent patient","volume":"14","author":"Chieosilapatham","year":"2024","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.jiac.2026.103065_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s15010-014-0609-1","article-title":"Disseminated Nocardia paucivorans infection in an immunocompetent host","volume":"42","author":"Hammoud","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2026.103065_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.resinv.2017.11.008","article-title":"Relationship between the duration of trimethoprim\/sulfamethoxazole treatment and the clinical outcome of pulmonary nocardiosis","volume":"56","author":"Tashiro","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.jiac.2026.103065_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s15010-024-02323-9","article-title":"Trimethoprim-sulfamethoxazole dosing and outcomes of pulmonary nocardiosis","volume":"53","author":"Yetmar","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2026.103065_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13669","article-title":"Trimethoprim\/sulfamethoxazole for nocardiosis in solid organ transplant recipients: Real-life data from a multicentre retrospective study","volume":"23","author":"Conan","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/nep.12201","article-title":"Complications and outcomes of trimethoprim\u2013sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients","volume":"19","author":"Mitsides","year":"2014","journal-title":"Nephrology"},{"key":"10.1016\/j.jiac.2026.103065_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/antibiotics14121188","article-title":"Linezolid serum concentration variability among critically ill patients based on renal function and continuous renal replacement therapy administration","volume":"14","author":"Agliardi","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2026.103065_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107661","article-title":"An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring","volume":"67","author":"Fres\u00e1n","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2026.103065_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12879-026-12600-7","article-title":"Risk factors for adverse events associated with trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected patients: a multicenter, retrospective, observational cohort study","volume":"26","author":"Idemitsu","year":"2026","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2026.103065_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/bmjebm-2018-111107","article-title":"Catalogue of bias: publication bias","volume":"24","author":"DeVito","year":"2019","journal-title":"BMJ Evid-Based Med"},{"key":"10.1016\/j.jiac.2026.103065_bib39","first-page":"4665","article-title":"Effects of different palliative jaundice reducing methods on immunologic functions in patients with advanced malignant obstructive jaundice","volume":"37","author":"Tang","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jiac.2026.103065_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","article-title":"Epidemiology of infections in cancer patients","volume":"161","author":"Zembower","year":"2014","journal-title":"Cancer Treat Res"},{"issue":"6","key":"10.1016\/j.jiac.2026.103065_bib41","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","volume":"2025","author":"Chen","year":"2020","journal-title":"MedComm"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:12:27Z","timestamp":1793261547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1341321X26001637"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103065","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary nocardiosis following pembrolizumab use: case report and literature review of nocardiosis associated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103065"}}